William C. Huang

PD25-03 TREATMENT WITH UGN-102 IN PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: 24-MONTH DURATION OF RESPONSE DATA FROM THE PHASE 3 ENVISION TRIAL

Sandip M. Prasad, Nikola V. Mihaylov, Pencho Genov, Vasyl Terzi et autres

IP02-23 DURATION OF RESPONSE TO UGN-102 BY AGE AT BASELINE ACROSS 3 CLINICAL TRIALS IN PATIENTS WITH LOW-GRADE INTERMEDIATE-RISK BLADDER CANCER

Ashish M. Kamat, William C. Huang, Neal D. Shore, Michael J. Louie et autres

Utility of Circulating Tumor DNA Monitoring in Postnephrectomy Renal Cancer

Raj Ramnik Bhanvadia, Michael B. Smigelski, Sumedha Sudhaman, Shavy Nagpal et autres

PURPOSE Increased heterogeneity in outcomes has been observed postnephrectomy in patients with renal cell carcinoma (RCC), with standard clinical parameters being primarily used for risk assessment. Currently, no blood-based biomarkers are available for molecular residual disease (MRD) detection in RCC. Herein, we …

us (code pays fourni par la source)

Imaging of Clinically Localized Prostate Cancer

Arman S. Walia, William C. Huang

us (code pays fourni par la source)

Abstract 165: PVRL2 upregulation by tumor-associated macrophages confers a regulatory phenotype and is associated with poor prognosis in high-grade serous ovarian cancer

Kosuke Murakami, Hirofumi Ando, Michele Y Doucet, Dacheng Ding et autres

Abstract Advanced or recurrent high-grade serous ovarian cancer (HGSOC) are associated with poor prognosis. While HGSOC is moderately immunogenic, anti-PD-1/L1 therapy has fared poorly in trials. PVRL2 (Nectin2) is both a cell-adhesion molecule as well as a ligand for PVRIG, a novel …

us (code pays fourni par la source)

Abstract 6374: The role of myeloid cell-expressed PVRL2 in high-grade serous ovarian cancer

Kosuke Murakami, Hirofumi Ando, Michele Y Doucet, William C. Huang et autres

Abstract Ovarian cancer (OC) is the fifth leading cause of cancer death in women in the United States. Standard of care (surgical resection and platinum-based chemotherapy) has limited survival benefit for patients with advanced disease. Since 3 of every 4 patients are …

us (code pays fourni par la source)

487 The Role of VSIG4 as an immuno-regulatory protein in cancer

William C. Huang, Michele Y Doucet, Rupashree Sen, Andrew Pardoll et autres

Background V-set and Ig domain-containing 4 (VSIG4; also known as CRIg) is a myeloid-restricted complement receptor indispensable for phagocytosis of C3-opsonized bacteria. Being a B7-family member, Vsig4 has also been described as a negative regulator of T cell activation. Murine Vsig4 expression …

us (code pays fourni par la source)